3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Lung Neoplasms
2
Venous Thromboembolism
1
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
19
atezolizumab
9
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
durvalumab
5
Ipilimumab
5
fludarabine
4
Trastuzumab
4
cemiplimab
3
cabozantinib
3
avelumab
3
Sunitinib
3
Biopsy
3
ulixertinib
2
toripalimab
2
tislelizumab
2
spartalizumab
2
sargramostim
2
relatlimab
2
palbociclib
2
lenvatinib
2
epacadostat
2
enzalutamide
2
cyclopropapyrroloindole
2
copanlisib
2
budigalimab
2
aldesleukin
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Rivaroxaban
×
Thoracic
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled